The DOI matches its Crossref record.
Screening for Prostate Cancer: A Decision Analytic View
Abstract
Objective. —To determine the clinical and economic effects of screening for prostate cancer with prostate-specific antigen (PSA), transrectal ultrasound (TRUS), and digital rectal examination (DRE). Design. —Decision analytic cost-utility analysis comparing four screening strategies with a strategy of not screening. We assumed that the cancer detection rate and stage distribution were predicted by each combination of tests and that localized cancer was treated with radical prostatectomy. For each strategy, we calculated life expectancy, quality-adjusted life expectancy (QALE), and cost-utility ratios for unselected and high-prevalence populations. Data. —Probabilities and rates for clinical events were gathered from published data. We assessed utilities by the time—trade-off method using urologists, radiation oncologists, and internists as subjects. The Clinical Cost Manager at the New England Medical Center provided cost data. Results. —In unselected men between the ages of 50 and 70 years, screening with PSA or TRUS prolonged unadjusted life expectancy but diminished QALE. Screening with DRE alone yielded no reduction in mortality at any age. All programs increased costs. Results were sensitive only to assumptions about the efficacy of treatment. In high-prevalence populations, screening produced a similar pattern: gains in unadjusted life expectancy, losses in QALE, and increased costs. Conclusions. —Our analysis does not support using PSA, TRUS, or DRE to screen asymptomatic men for prostatic cancer. Screening may result in poorer health outcomes and will increase costs dramatically. Assessment of comorbidity, risk attitude, and valuation of sexual function may identify individuals who will benefit from screening, but selecting high-prevalence populations will not improve the benefit of screening. (JAMA. 1994;272:773-780)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Etzioni, R. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.13.981 · Cited by 949
Potosky, A. L., Davis, W. W., Hoffman, R. M., Stanford, J. L., Stephenson, R. A., Penson, D. F., & Harlan, L. C. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh259 · Cited by 680
The Role of Increasing Detection in the Rising Incidence of Prostate Cancer
Potosky, A. L. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520310046028 · Cited by 674
Metadata
- Authors
- Krahn, M. D.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1994-09-14
- Volume
- 272
- Issue
- 10
- Pages
- 773
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4313371767
- Cited by
- 199
- References
- 0
- FWCI
- 17.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening for Prostate Cancer: A Decision Analytic View. https://app.cochat.ai/papers/10.1001/jama.1994.03520100035030
- The paper
- Krahn, M. D. (1994). Screening for Prostate Cancer: A Decision Analytic View. JAMA. https://doi.org/10.1001/jama.1994.03520100035030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.